Free Fatty Acid Receptor Activator

Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC₅₀ of 72 nM.

GPR40 Activator 2 is a potent GPR40 activator from patents WO 2012147516 A1, WO 2012046869A1 and WO 2011078371 A1.

GPR40 Activator 3 (compound SC) is a potent GPR40 activator. GPR40 Activator 3 mitigates pulmonary fibrosis by inhibiting M2 macrophage polarization via the GPR40/PKD1/CD36 axis.

HDAC6-IN-61 (Compound 4e) is a HDAC6 inhibitor (IC₅₀: 73 nM) with selectivity over other HDAC isoforms. HDAC6-IN-61 is also a GPR40 activator. HDAC6-IN-61 increases acetylated tubulin and ERK phosphorylation levels. HDAC6-IN-61 can be used for research of neuroinflammation such as Alzheimer's disease.

GPR40 Activator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC₅₀ of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury.

Fasiglifam (Standard) is the analytical standard of Fasiglifam (HY-10480). This product is intended for research and analytical applications. Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC₅₀ of 72 nM.